Zymedi Announces "rapaprutug" as the International Nonproprietary Name (INN) for ZMA001
- Written by PR Newswire
INCHEON, South Korea, Dec. 8, 2025 /PRNewswire/ -- Zymedi (CEO Sunghoon Kim) announced that the World Health Organization (WHO) has assigned rapaprutug as the International Nonproprietary Name (INN) for the company's first-in-class antibody therapy ZMA001, being developed as a treatment for pulmonary arterial hypertension (PAH).
The assignment of...
Read more: Zymedi Announces "rapaprutug" as the International Nonproprietary Name (INN) for ZMA001














